65,437 trials
Healthy
Primary: Cmax (Maximum Observed Concentration) — 53.89; 55.19 µg/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 21.625; 23.501 mcg/mL
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Healthy
Primary: Cmax (Maximum Observed Concentration) — 14802.55; 14808.74 pg/mL
Healthy
Primary: Cmax - Maximum Observed Concentration — 19.635; 20.054 mcg/mL
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Changes From Study Period II Baseline (Week 0) to Weeks 3, 4, 6, 8, and 12 in Positive and Negative Syndrome Scale (PANSS) Total Score in Early Onset Response and Not…
Healthy
Primary: Cmax - Maximum Observed Concentration — 612.45; 604.85 ng/mL
Perennial Allergic Rhinitis · Obstructive Sleep Apnea · Sleep Disorder
Primary: Apnea-Hypopnea Index — 1.0; 1.6 apnea-hypopnea episodes per hour — p=0.9219
Priapism · Anemia, Sickle Cell
Primary: Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia. — 18; 58; 160; 189 participants
Chronic Hepatitis B
Primary: Mean Change From Baseline in Hepatitis B Virus (HBV) DNA at Week 52 — -3.69; -3.40 log10 copies/mL — p=<0.001
HIV Infections
Primary: Total Glutathione — 1,964; 3,490; 1,865; 3,995 nmoles glutathione/ ml of sample — p=<0.05
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) — 131.0; 42.0 Days
Mood Disorders
Primary: Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease…
Hypertension
Primary: Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment — 139; 137; 64; 64 Participants — p=0.8822
Healthy
Primary: Calcium Absorption — 30.4; 25.4 percentage of Calcium-47 absorbed — p=0.02